Ten‐year disease free survival after transperineal sonography‐guided iodine‐125 brachytherapy with or without 45‐gray external beam irradiation in the treatment of patients with clinically localized, low to high gleason grade prostate carcinoma

The authors report observed 10‐year brachytherapy results in the treatment of 152 consecutive patients with clinically organ‐confined prostate carcinoma.

[1]  P. Schellhammer,et al.  Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate. , 1993, Urology.

[2]  G. Zagars.  The prognostic significance of a single serum prostate-specific antigen value beyond six months after radiation therapy for adenocarcinoma of the prostate. , 1993, International journal of radiation oncology, biology, physics.

[3]  J. Oesterling,et al.  Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. , 1994, The Journal of urology.

[4]  S. Leibel,et al.  Patterns of care outcome studies: results of the national practice in adenocarcinoma of the prostate. , 1984, International journal of radiation oncology, biology, physics.

[5]  K. Rosenzweig,et al.  Prostate specific antigen following radiotherapy for local prostate cancer. , 1995, The Journal of urology.

[6]  1056 Conformal brachytherapy boost to external beam irradiation for clinically localized high risk prostate cancer , 1995 .

[7]  T. Stamey,et al.  Identification of residual cancer in the prostate following radiation therapy: role of transrectal ultrasound guided biopsy and prostate specific antigen. , 1989, The Journal of urology.

[8]  S. Smalley.  The effect of dose on local control of prostate cancer. , 1989, International journal of radiation oncology, biology, physics.

[9]  D. Paulson.  Impact of radical prostatectomy in the management of clinically localized disease. , 1994, The Journal of urology.

[10]  P. Scardino,et al.  Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? , 1994, The Journal of urology.

[11]  J. Payne,et al.  Original Articles: Prostate Cancer , 1995 .

[12]  J. Adolfsson,et al.  Deferred treatment of clinically localized low-grade prostate cancer: actual 10-year and projected 15-year follow-up of the Karolinska series. , 1998, Urology.

[13]  S. Hancock,et al.  Prostate specific antigen after radiotherapy for prostate cancer: a reevaluation of long-term biochemical control and the kinetics of recurrence in patients treated at Stanford University. , 1995, The Journal of urology.

[14]  W. Catalona,et al.  Artificial neural networks in the diagnosis and prognosis of prostate cancer: a pilot study. , 1994, The Journal of urology.

[15]  N. Smith,et al.  The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies. , 1995, The Journal of urology.

[16]  K. Wallner,et al.  Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostatic cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Hanlon,et al.  Conformai external beam treatment of prostate cancer , 1997 .

[18]  Peter D. Grimm,et al.  Use of Transrectal Ultrasound in Transperineal 125Iodine Seeding for Prostate Cancer: Methodology , 1989 .

[19]  Anatomic localization of radioactive gold seeds of the prostate by computer-aided tomography. , 1981, Computerized tomography.

[20]  E. Crawford,et al.  PSA as a screening test for prostate cancer. , 1993, The Urologic clinics of North America.

[21]  W. Whitmore,et al.  Retropubic implantation to iodine 125 in the treatment of prostatic cancer. , 1972, The Journal of urology.

[22]  Y. Tanahashi,et al.  Transrectal ultrasonotomography of the prostate. , 1975, The Journal of urology.

[23]  P. Walsh,et al.  Pathological stage is higher in older men with clinical stage B1 adenocarcinoma of the prostate. , 1989, The Journal of urology.

[24]  C. Ed,et al.  PSA as a screening test for prostate cancer. , 1993 .

[25]  R. B. Smith,et al.  The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. , 1994, The Journal of urology.

[26]  P. Schellhammer,et al.  Prostate biopsy after definitive treatment by interstitial 125iodine implant or external beam radiation therapy. , 1987, The Journal of urology.

[27]  F. Mostofi,et al.  Characteristics of prostate cancer detected in the American Cancer Society-National Prostate Cancer Detection Project. , 1994, The Journal of urology.

[28]  J. Payne,et al.  Detailed preliminary analysis of 125iodine implantation for localized prostate cancer using percutaneous approach. , 1995, The Journal of urology.

[29]  H. Holm,et al.  Ultrasonically guided puncture technique , 1980 .

[30]  A. Zietman,et al.  Radical prostatectomy and radical radiation therapy for clinical stages T1 to 2 adenocarcinoma of the prostate: new insights into outcome from repeat biopsy and prostate specific antigen followup. , 1994, The Journal of urology.

[31]  P. Guinan,et al.  Prostatorectal fistula associated with 125iodine seed radiotherapy. , 1983, The Journal of urology.

[32]  I. Kaplan,et al.  Prostate specific antigen after external beam radiotherapy for prostatic cancer: followup. , 1993, The Journal of urology.

[33]  A. Zietman,et al.  The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. , 1995, International journal of radiation oncology, biology, physics.

[34]  A. Moss,et al.  Value of computed tomography in interstitial 125I brachytherapy of prostatic carcinoma. , 1983, Radiology.

[35]  T. Schultheiss,et al.  Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. , 1995, The Journal of urology.

[36]  Permanent interstitial implantation using palladium-103: the New York Medical College preliminary experience. , 1992, International journal of radiation oncology, biology, physics.

[37]  T. Stamey,et al.  The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients. , 1993, The Journal of urology.

[38]  J. Montie,et al.  Frequency of residual neoplasm in the prostate following three‐dimensional conformal radiotherapy , 1993, The Prostate.

[39]  D. Kuban,et al.  Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer. , 1995, International journal of radiation oncology, biology, physics.

[40]  J. Blasko,et al.  Interstitial iodine‐125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma , 1997, Cancer.

[41]  A W Partin,et al.  Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. , 1993, The Urologic clinics of North America.

[42]  G. Zagars.  Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy. , 1994, The Journal of urology.

[43]  A. Zietman,et al.  Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. , 1994, The Journal of urology.

[44]  W. Catalona,et al.  5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. , 1994, The Journal of urology.

[45]  W Cavanagh,et al.  Brachytherapy for clinically localized prostate cancer: results at 7- and 8-year follow-up. , 1997, Seminars in surgical oncology.